HSL Mobile App
PE Ratio
Is the price-earnings ratio for valuing a company that measures its current share price relative to its earnings per share.
P/E RATIO
EPS
The earnings per share ratio is a portion of company's net profit allocated for each outstanding share. It is calculated by deducting preferred stock divided from the net income of the company divided by the number of outstanding shares.
EPS
PRICE/BOOK
Price-to-book ratio is used to compared the company's current market price with its book value.
PRICE/BOOK
Deliverable
These are the acutal number of shares that are traded on delivery based, meaning transfered from one person to another during the day's trade.
DELIVERABLES
DIV YIELD.(%)
Dividend Yield measures the quantum of cash dividends paid to shareholders in a financial year relative to the market value of the per share.
DIV YIELD.(%)
Company Details
Check out the key parameters of the company to understand the financial health and stock performance
-
TechnicalThe key levels help you plan your entry and exit point.
-
Profit & LossTake a quick look at the revenues and expenditure sheet.
-
Balance SheetIts a statement of assets, liabilities and share capital.
-
Dividend HistoryCheck out the detailed payout data over the last three years.
-
Comparative ReturnsReveals how the stock has fared compared to the BSE, NSE benchmark indices.
Key Level
Resistance 1
-
-
Resistance 2
-
-
Support 1
-
-
Support 2
-
-
Moving Average
20 Days
-
-
50 Days
-
-
100 Days
-
-
200 Days
-
-
Growth in 3 years
Sales
Sales Industry Avg
PAT
PAT Industry Avg
Sales Industry Avg
PAT
PAT Industry Avg
Growth in 3 years
Total Asset Growth
26.45%
Total Liabilities growth
9.50%
Reserves Change
-6.41%
26.45%
Total Liabilities growth
9.50%
Reserves Change
-6.41%
Relative to Sensex rtn in 3 year
Relative to Nifty rtn in 3 year
Relative to top 3 MF rtn in 3 year
Relative to Nifty rtn in 3 year
Relative to top 3 MF rtn in 3 year
| 2016 | 2014 | 2014 | |
|---|---|---|---|
| Sales | 59.91 | 59.91 | 59.91 |
| Gross Profit | 60.14 | 60.14 | 60.14 |
| Operating Profit | 6.14 | 6.14 | 6.14 |
| Sales | 59.91 | 59.91 | 59.91 |
| Gross Profit | 60.14 | 60.14 | 60.14 |
| Operating Profit | 6.14 | 6.14 | 6.14 |
Peer Companies
A quick glance on how stocks from the same sector have performed along with some key parameters
Return Calculator
This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.
If I had made
investment of
in
Months Ago
with a
frequency
for
Months
in
My investment would be worth with a of %
Our Research Reports
Stocks and sector-wise Research Reports by HDFC securities help you analyse, understand and take a informed investment decision.
Report
Corporate Action
Find out the historical dividend payout and other corporate actions including bonus, stock split and rights issue etc.
Our Research Analysis
As of today
18.2%
Target Achived
18.2%
Target Achived
This call still has potential to give significant positive returns
Potential Upside
+22.8%
Buy Call with 3 month time frame
+22.8%
Buy Call with 3 month time frame
CMP : 1758
Target : 1658
Stop Loss : 1858
Reco Price : 1858
Call Type : 1858
Reco Date :12/09/2016
Rationale
History
|
15
jan 2016 |
Call initiated Cmp: 1875 |
Target: 1875 | Reco: 1875 | Stop loss: 1875 | Upside: 1875 |
|
15
jan 2016 |
Call initiated Cmp: 1875 |
Target: 1875 | Reco: 1875 | Stop loss: 1875 | Upside: 1875 |
|
15
jan 2016 |
Call initiated Cmp: 1875 |
Target: 1875 | Reco: 1875 | Stop loss: 1875 | Upside: 1875 |
As of today
__PERCENT__%
Target Achived
__PERCENT__%
Target Achived
This call still has potential to give significant positive returns
Potential Upside
__TARGETRETURN__%
Buy Call with __TIMEFRAME__ time frame
CMP : __CMP__
Target : __TARGET__
Stop Loss : __STOPLOSS__
Reco Price : __RECOPRICE__
Reco Date :__RECODATE__
Call Type :__CALLTYPE__
__Rationale__
__RECOTYPE__ __COMPANY_NAME__
|
__DATE__
__MONTHYEAR__ |
Call initiated Target: __TARGET__ |
Target Gain __TG__ % | Reco Price: __RP__ | Stop loss: __SL__ | HORIZON : __HORIZN__ |
Our View __RECOTYPE__
FnO
A snapshot on how the stock has performed in the derivatives segment on a real-time basis.
__Name__ __LTP__ Chg: __ChangePer__ Expiry Month __Date__
Day's Low
__DaysLow__
__DaysLow__
Day's High
__DaysHigh__
__DaysHigh__
Day’s Open
__DaysOpen__
__DaysOpen__
Prev Close
__PreviousClose__
__PreviousClose__
Volume
__Volume__
__Volume__
OI
__OI__
__OI__
OI Change (%)
__OIPer__
__OIPer__
MF Holdings
Here's a list of major funds which hold the stock in their portfolio as of the last reported quarter.
| Scheme Name | AUM (%) | CMV ( in Cr.) | Holding Date |
|---|---|---|---|
| Aditya Birla Nuvo Ltd | 35.67 | 35.67 | 35.67 |
| Aditya Birla Nuvo Ltd | 35.67 | 35.67 | 35.67 |
| Aditya Birla Nuvo Ltd | 35.67 | 35.67 | 35.67 |
| Aditya Birla Nuvo Ltd | 35.67 | 35.67 | 35.67 |
| Aditya Birla Nuvo Ltd | 35.67 | 35.67 | 35.67 |
News
Stay tuned to the latest developments and happenings in the company.
CuraTeQ Biologics receives UK MHRA approval for oncology biosimilar Bevqolva
CuraTeQ Biologics s.r.o., a step-down subsidiary of Aurobindo Pharma, announced that it has obtained marketing authorisation from UK`s Medicin....
23 Dec 2024 16:13CuraTeQ Biologics received recommendation of a marketing authorisation for Zefylti
CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, announced that the Committee for Medicinal Products for Human Use (CHMP) wi....
13 Dec 2024 18:31Eugia Pharma Specialities receives USFDA approval for Pazopanib Tablets 200mg
Aurobindo Pharma announced that its wholly owned subsidiary company, Eugia Pharma Specialities, has received final approval from the US Food &....
05 Dec 2024 14:55Aurobindo Pharma consolidated net profit rises 7.95% in the September 2024 quarter
Net profit of Aurobindo Pharma rose 7.95% to Rs 817.38 crore in the quarter ended September 2024 as against Rs 757.18 crore during the previous quarte....
11 Nov 2024 07:30Aurobindo Pharma consolidated net profit rises 61.05% in the June 2024 quarter
Net profit of Aurobindo Pharma rose 61.05% to Rs 919.22 crore in the quarter ended June 2024 as against Rs 570.75 crore during the previous quarter en....
12 Aug 2024 07:32Aurobindo Pharma consolidated net profit rises 79.50% in the March 2024 quarter
Net profit of Aurobindo Pharma rose 79.50% to Rs 908.75 crore in the quarter ended March 2024 as against Rs 506.27 crore during the previous quarter e....
27 May 2024 08:39__heading__
Published on __date__ at __time__
__description__
Corporate News
Subscribe for our
newsletter
newsletter
